Skip to content

Etomidate and propofol in intravenous anesthesia for daytime quality of postoperative recovery of patients with laparoscopic cholecystectomy: a multicenter, prospective, randomized, controlled, non inferior effect research

Etomidate and propofol in intravenous anesthesia for daytime quality of postoperative recovery of patients with laparoscopic cholecystectomy: a multicenter, prospective, randomized, controlled, non inferior effect research

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400087413
Enrollment
Unknown
Registered
2024-07-26
Start date
2024-10-15
Completion date
Unknown
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gallbladder disorders

Interventions

Etomidate:Total intravenous anesthesia with etomidate
Propofol:Total intravenous anesthesia with propofol

Sponsors

Nanjing Drum Tower Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Age range: 18 to 65 years old; 2) Day surgery; 3) Scheduled to undergo laparoscopic cholecystectomy under general anesthesia; 4) Agree to participate in this study and have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Refusal to participate in this study; 2) ASA classification grade III or above; 3) BMI less than 18.5 kg/m² or greater than 29.9 kg/m²; 4) History of chronic analgesic or sedative drug use, including benzodiazepines, alcohol abuse, or allergy to etomidate or propofol; 5) History of insomnia; 6) Severe preoperative cognitive impairment with MMSE score = 20; 7) Inability to understand assessment scales such as QoR-15; 8) Inability to self-care prior to surgery; 9) Cerebrovascular accident, myocardial infarction, or unstable angina within the last 3 months; severe hepatic or renal dysfunction; preoperative blood pressure = 180 mmHg; 10)Undergone surgery within the last 3 months; participation in another study within the last 30 days; 11) Patients who have taken hormones or other immunosuppressive drugs for more than 10 days in the past 6 months, or have a history of adrenal cortex suppression or immune system disorders.

Design outcomes

Primary

MeasureTime frame
QoR-15;

Secondary

MeasureTime frame
Postoperative hospital complications (comprehensive complications);Response time to verbal commands and extubation time;PACU stay time;Patient self-reported pain, anesthesia comfort, and satisfaction;Injection pain;Time to loss of consciousness;Incidence of hypertension and hypotension;Incidence of Delirium;Incidence of PONV;Severity of nausea;Frequency of vomiting;PAIN;Intraoperative awareness;Incidence OF COMPLICATIONS;The long-term quality of life;Myoclonus;

Countries

China

Contacts

Public ContactXiaoping Gu

Nanjing Drum Tower Hospital

xiaopinggu@nju.edu.cn+86 138 1399 6903

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026